Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

BACKGROUND: Survival-based surrogate endpoints such as progression-free survival (PFS) are commonly used in oncology clinical trials. The evaluation-time bias in the assessment of median disease progression in randomized trials has been suggested by several simulation studies, but never demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaille, T., Moreau Bachelard, C., Coquan, E., du Rusquec, P., Paoletti, X., Le Tourneau, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733185/
https://www.ncbi.nlm.nih.gov/pubmed/34979424
http://dx.doi.org/10.1016/j.esmoop.2021.100366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733185/
https://www.ncbi.nlm.nih.gov/pubmed/34979424
http://dx.doi.org/10.1016/j.esmoop.2021.100366

Ejemplares similares